Jacob J - Search Results

1

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Bicher A, et al. Among authors: jacob j. Cancer. 1993 Jan 15;71(2 Suppl):594-600. doi: 10.1002/cncr.2820710216. Cancer. 1993. PMID: 7678382 Clinical Trial.

2

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.

Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC, Ozols RF, VanderMolen L, Kohn E, Jacob JL, et al. Reed E, et al. Among authors: jacob jl. J Clin Oncol. 1993 Nov;11(11):2118-26. doi: 10.1200/JCO.1993.11.11.2118. J Clin Oncol. 1993. PMID: 8229126

3

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E. Sarosy G, et al. Among authors: jacob j. J Clin Oncol. 1992 Jul;10(7):1165-70. doi: 10.1200/JCO.1992.10.7.1165. J Clin Oncol. 1992. PMID: 1376773 Clinical Trial.

4

Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.

Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M. Reed E, et al. Among authors: jacob j. Semin Oncol. 1995 Jun;22(3 Suppl 6):90-6. Semin Oncol. 1995. PMID: 7541159 Review.

5

The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.

Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO, Jacob J, Christian M, Reed E. Bicher A, et al. Among authors: jacob j. Anticancer Drugs. 1993 Apr;4(2):141-8. doi: 10.1097/00001813-199304000-00003. Anticancer Drugs. 1993. PMID: 7683933

6

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.

Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA. Kohn EC, et al. Among authors: jacob j. Cancer Res. 1996 Feb 1;56(3):569-73. Cancer Res. 1996. PMID: 8564973 Clinical Trial.

7

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.

Reed E, Sarosy G, Kohn E, Christian M, Link CJ Jr, Goldspiel B, Davis P, Jacob J, Maher M. Reed E, et al. Among authors: jacob j. Gynecol Oncol. 1996 Jun;61(3):349-53. doi: 10.1006/gyno.1996.0155. Gynecol Oncol. 1996. PMID: 8641614 Clinical Trial.

8

5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.

Reed E, Jacob J, Ozols RF, Young RC, Allegra C. Reed E, et al. Among authors: jacob j. Gynecol Oncol. 1992 Sep;46(3):326-9. doi: 10.1016/0090-8258(92)90226-9. Gynecol Oncol. 1992. PMID: 1526510

9

Measures of renal function in patients with cisplatin-related chronic renal disease.

Reed E, Jacob J, Brawley O. Reed E, et al. Among authors: jacob j. J Natl Med Assoc. 1991 Jun;83(6):522-6. J Natl Med Assoc. 1991. PMID: 1865503 Free PMC article.

10

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.

Kohn EC, Sarosy GA, Davis P, Christian M, Link CE, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A, Reed E. Kohn EC, et al. Among authors: jacob j. Gynecol Oncol. 1996 Aug;62(2):181-91. doi: 10.1006/gyno.1996.0213. Gynecol Oncol. 1996. PMID: 8751547 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,028 results

Search Page

Filters